In our study, the tendency to undergo activation of the acidic sphingomyelinase gene was observed (4.5 times, p = 0.09, Figure 2b), whereas the neutral sphingomyelinase gene was slightly activated (1.5 times, p = 0.15, Figure 2a) during pregnancy in the course of breast cancer treatment (Figure 2). The gene discussed is SMPD2; the disease is breast cancer.